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Animal-assisted therapy (AAT) is increasingly researched as a potential treatment for 
physical and mental illness, including schizophrenia. The aim of the current paper is to 
systematically review randomised controlled trials (RCTs) to assess the effectiveness of AAT 
for schizophrenia and related disorders. We searched PubMed, PsycINFO, CINAHL, EMBASE, 
The Cochrane Library, CAB Abstracts, and Web of Science for RCTs of AAT for schizophrenia 
and related disorders. Primary outcomes were mental state and behaviour, clinical global 
response, and quality of life and wellbeing. Studies were eligible if they were RCTs that had 
compared AAT, or other animal-assisted intervention, to any control group using any 
participants with a clinical diagnosis of schizophrenia (or related disorder), regardless of age, 
gender, setting, or severity and duration of illness. Seven studies were identified for the 
review. Meta-analysis was not possible due to heterogeneity of studies, including marked 
differences in outcome measures and interventions. Five out of seven studies included 
symptoms as an outcome measure, with one reporting improvements in negative symptoms 
and one study reporting improvements in positive and emotional symptoms. The remaining 
studies reported no significant effects of AAT. Three studies included quality of life as an 
outcome measure but did not find any significant effects. Two studies did, however, report 
improvements in various measures of self-view. The use of AAT for schizophrenia remains 
inconclusive and there is currently not enough evidence to draw any firm conclusions due to 
heterogeneity of studies, risk of bias, and small samples. Rigorous, large-scale RCTs are 
needed to assess the true impact of AAT on schizophrenia.  
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Schizophrenia is typically a severe illness that is treated with antipsychotic 
medication, but outcomes are often poor, with a meta-analysis finding a recovery rate of 
only 13.5% meaning that only approximately 1 in 7 individuals met the criteria for recovery 
(Jääskeläinen et al., 2012). Antipsychotic drugs are largely effective for positive symptoms, 
but they have lower efficacy for negative symptoms (Leucht & Davis, 2017). 
Psychotherapies are often used in conjunction with antipsychotic medication. Examples of 
psychotherapies for schizophrenia include cognitive behavioural therapy (CBT), family 
therapy, and arts therapies. Results from cognitive behavioural therapies have been mixed, 
particularly over time, with one meta-analysis finding that older studies found stronger 
treatment effects than more recent studies (Velthorst et al., 2014). A recent Cochrane 
review also failed to find any evidence for the effectiveness of CBT over other psychosocial 
therapies for schizophrenia, including family therapy, supportive therapy, and other talking 
therapies (Jones et al., 2018). There is limited evidence for the use of social skills training to 
improve social skills in schizophrenia patients (Almerie et al., 2015), limited evidence for the 
use of family therapies in reducing the number of relapse events and hospitalizations of 
schizophrenia patients (Pharoah et al., 2010), and limited evidence for the use of art 
therapies in reducing negative symptoms (as measured using the Scale for the Assessment 
of Negative Symptoms (SANS); Ruddy & Milnes, 2005). It is therefore important that other 
alternative treatments and adjuncts are developed to improve outcomes in the management 
of schizophrenia.  
Recently, there has been a rapid increase in the use of animal-assisted therapies for 
a wide range of mental and physical illnesses, including schizophrenia. However, evidence 
for the effectiveness of animal-assisted therapies for schizophrenia remains unclear. Pet 
Partners (formerly Delta Society) defines animal-assisted therapy (AAT) as ‘a goal-oriented, 
planned, structured, and documented therapeutic intervention directed by health and human 
service providers as part of their profession’ (Pet Partners, 2018). This review will also 
include animal-assisted activities (AAA), which Pet Partners defines as ‘opportunities for 
motivational, educational, and/or recreational benefits to enhance quality of life…delivered 
by a specially trained professional, paraprofessional, and/or volunteer,’ with an animal that 
‘meets specific criteria for suitability.’ Animal-assisted therapy is a more structured 
intervention than animal-assisted activities, with a greater focus on improvements in 
functioning, which are documented and evaluated throughout the process. Pet therapy is a 
broader term that includes AAT and AAA. The use of animals in therapy was first popularised 
during the 1960’s (Levinson & Mallon, 1997). Animals have since been incorporated into 
treatments for a number of illnesses including heart disease, stroke, depression, cancer, and 
dementia and AAT is typically used to promote improvements in emotional, social support, 
cognitive, and physical functioning. Animal-assisted therapy is typically used as an adjunct 
to other treatments and interventions (Nimer & Lundahl, 2007). Studies evaluating AAT have 
shown mixed results. Some studies have shown promising results, including lower systolic 
pulmonary artery pressure, lower neurohormone levels, and lower anxiety in heart failure 
patients (Cole et al., 2007), improvements in quality of life and mental health in stroke 
patients (Beinotti et al. (2013), reduction in symptoms of depression (Antonioli & Reveley, 
2005), and improved global functioning in adolescents with acute mental disorders (Stefanini 
et al., 2015). However, some studies have failed to find any significant effects of animal-
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assisted therapy. For example, studies have found no improvement to quality of life, gross 
motor function, and health in children with cerebral palsy (Davis et al., 2009), no 
improvement in mood or perceived health in cancer patients (Johnson et al., 2008), and no 
improvement in self-care functioning, disoriented behaviour, depressed or anxious mood, 
irritable behaviour, or withdrawn behaviour in geriatric psychiatry patients (Zisselman et al., 
1996). 
Animal-assisted therapy may be useful in the treatment of schizophrenia and related 
disorders when used as an adjunct to standard treatment for a number of reasons. 
Schizophrenia is characterized by positive and negative symptoms. Positive symptoms are 
those that are added to normal human experience and negative symptoms are those that 
are taken away from normal human experience. Animal-assisted therapy may be particularly 
useful in targeting negative symptoms. Negative symptoms that could be targeted by AAT 
include blunted affect, emotional withdrawal, poor rapport, passive/apathetic social 
withdrawal, and lack of spontaneity and flow of conversation. Given that two of the targets 
of AAT are to improve social and emotional functioning, it could be a valuable tool in 
schizophrenia treatment. There are a number of mechanisms by which animals may improve 
symptoms and functioning in schizophrenia. Oxytocin is one such mechanism. Administration 
of intranasal oxytocin is associated with a reduction of symptoms (as measured by the 
Positive and Negative Symptoms Scale (PANSS)) and improvements in social cognition in 
schizophrenia patients (Pedersen et al., 2011). Interacting with an animal has been shown 
to increase oxytocin levels in humans (Odendaal & Mientjes, 2003), and so could improve 
symptoms and social functioning through oxytocin release. Another mechanism is the role of 
the animal as a social catalyst to increase social interactions with others (McNicholas & 
Collis, 2006). Animal-assisted therapy has been shown to increase verbal interactions 
between nursing home residents (Fick, 1993), and increase initiation and participation in 
longer conversations (Bernstein et al., 2000). Animal-assisted therapy could improve 
motivation in patients to attend and participate in therapy sessions (Holcomb & Meacham, 
1989). This is particularly important given the high rates of disengagement (up to one third) 
from care among individuals with serious mental illness (Kreyenbuhl et al., 2009). Animals 
have further been shown to improve rapport between patients and professionals with 
substance abuse patients rating the therapeutic alliance with their therapist as more positive 
after taking part in animal-assisted therapy (Wesley et al., 2009). This may be because of 
the animal’s role as a non-judgemental and accepting presence in therapy sessions (Friesen, 
2007). Animal-assisted therapy has been associated with a number of improvements in 
emotional functioning. Animal-assisted therapy is associated with moderate improvements in 
emotional wellbeing (Nimer & Lundahl, 2007), increased expression of emotions in children 
with acute mental disorders (Stefanini et al., 2016), and animal-assisted activities have been 
associated with increases in positive emotions in patients with Alzheimer’s (Mossello et al., 
2011). 
While the use of AAT in the treatment of schizophrenia has received increased 
attention, it is important at this stage to thoroughly review both published and non-
published studies to assess the effectiveness of AAT for schizophrenia, to assess the quality 
of the methods used, and guide future research. We aimed to systematically review 
evidence from randomised controlled trials to assess the effectiveness of animal-assisted 
therapy, compared to any control, for the treatment of schizophrenia and related disorders. 
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A further aim of the current review was to assess outcomes relating to the feasibility and 
potential barriers of providing AAT for schizophrenia patients, and to make 
recommendations for future research. 
 
Methods 
The systematic review was conducted following PRISMA guidelines (Moher et al., 
2009). Meta-analysis was not possible due to heterogeneity, with marked differences in 
outcome measures and interventions.  
 
Search strategy and selection criteria 
Searches were carried out in the following electronic databases covering all dates up 
to 27th September 2017: PubMed, PsycINFO, CINAHL, EMBASE, The Cochrane Library (trials 
database), CAB Abstracts, Web of Science. The search strategy for EMBASE is provided in 
Table 1. Search terms for animal-assisted therapy were formulated by adapting a 
comprehensive search strategy used in another systematic review of animal-assisted 
interventions (AAIs; O'Haire et al., 2015). Hand searches of reference lists and citation 
tracking, using Google Scholar and Web of Science, were conducted for the final list of 





Reference manager software (EndNote X8.2) was used to collate articles and to 
remove duplicates. Title and abstract screening was carried out by one reviewer (EH). Full 
text articles were then retrieved for the remaining list of studies and full-text screening was 
carried out independently by two reviewers (EH and RH), with disagreements being noted 
and resolved through discussion or were further discussed with SL where an agreement 
could not be reached.  
Studies were eligible to be included in the review if they were randomised controlled 
trials that had compared animal-assisted therapy, or other animal-assisted intervention, to a 
control group using any participants with a clinical diagnosis of schizophrenia or related 
disorder, including schizophreniform disorder and schizo-affective disorder, regardless of 
age, gender, setting, or severity and duration of illness. Only studies reported in the English 
language were considered for the review. 
We decided to include all schizophrenia-related disorders for the sake of inclusivity 
due to the limited amount of research in this area. 
 
Outcomes 
Primary outcomes were mental state and behaviour (particularly changes in positive 
and negative symptoms), clinical global response, and quality of life and wellbeing as 
measured using any relevant scale, such as the Quality of Life Scale (QLS; Heinrichs et al., 
1984) or the EuroQol Five Dimensions Questionnaire (EQ-5D; EuroQol, 1990).  
 Secondary outcomes were service use (any relevant scale, such as the Service 
Engagement Scale (SES; Tait et al., 2002), social functioning (any relevant scale such as the 
Index of Social Engagement (ISE; Mor et al., 1995), Social Functioning Scale (SFS; 
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Birchwood et al., 1990), Assessment of Interpersonal Problem Solving Skills (AIPSS; 
Donahoe et al., 1990), Living Skills Profile (LSP; Rosen et al., 1989), or behavioural 
observation of social functioning), medication, general functioning, physical health/activity, 
activities of daily living (ADL), and adverse effects (such as phobias, allergies, injury, suicide, 
or other cause of mortality).  
 
Data extraction and risk of bias assessment 
Data were extracted independently by two reviewers (EH and RH) using data 
extraction forms that were piloted on a limited selection of articles prior to conducting the 
full data extraction. Data were extracted for the following: diagnosis and diagnostic criteria, 
severity of illness, current treatment, sample size, gender, age, type of intervention, control 
condition, duration of treatment, length and frequency of treatment, animal/s used, 
outcomes, and key findings. Data are presented in Table 2. 
The final selection of articles were independently assessed for risk of bias by two 
reviewers (EH and RH) using the Cochrane risk of bias tool (Higgins et al., 2011). Consensus 
was reached through discussion or was further discussed with SL where an agreement could 
not be reached. Data from the risk of bias assessment were input into Review Manager 
(RevMan) 5.3 where the summary figure was generated. 
   
Results 
 The initial search retrieved 3956 articles (Figure 1). After removing duplicates there 
were 2963 studies for screening. 2932 records were removed after title and abstract 
screening. At full-text screening, a total of 24 studies were excluded. Reference lists of the 
remaining articles were hand searched to identify any additional studies. Two further studies 
were identified during citation tracking, but both were excluded. This left seven studies for 
detailed review. Full-text articles were available for six studies. The remaining study was a 
conference abstract. One study had an additional report. 
      
[Figure 1] 
 The total number of participants randomised was 390. Sample sizes ranged from 20 
to 105 participants (mean 55.7, SD 40.2). Mean ages ranged from 34.7 years to 79.1 years 
(mean 50.9, SD 16.7). Of those that reported the gender or sex of participants, there were 
166 females and 179 males. One study randomised 105 participants but only provided 
demographic information for the 90 participants that completed the study. Reporting of sex 
and gender were inconsistent across the studies. Two studies used the term ‘gender,’ 
(references), two studies used the term ‘sex,’ and one study only made reference to ‘males’ 
and ‘females.’ No definitions of terms were included in any of the studies. 
Participants were recruited from hospital populations. Six studies included inpatients 
only and one study included both inpatients and outpatients. Five studies included only 
individuals with a diagnosis of schizophrenia. One study included multiple diagnoses with 
individuals with a diagnosis of schizophrenia and schizotypal disorders forming the largest 
diagnosis group (37.7%). The remaining study included patients with a diagnosis of 
schizophrenia or schizoaffective disorder (76%), and patients with an affective or other 
disorder (24%). Patients were diagnosed using DSM-IV criteria (n=4) or ICD criteria (n=1). 
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One study used chart diagnosis, and the remaining study did not report diagnostic criteria. 
Studies were conducted in Spain (n=2), Taiwan (n=2), Israel (n=1), Norway (n=1), and in 
the USA (n=1). 
 Interventions included animal-assisted therapy (n=5), animal-assisted activity (AAA; 
n=1), and pet therapy (n=1). Test conditions included AAT in addition to standard 
treatment (n= 4). Detailed information was not provided for three studies. Comparison 
conditions included standard treatment (n=2), standard treatment plus an activity from a 
functional program (n=1), reading and discussion of current news (n=1), and standard 
treatment plus a novel intervention without a therapy dog (n=1). One study included two 
comparison conditions, which were regular hospital care and an active control group 
involving social skills exercises. One study did not provide any information regarding the 
comparison condition. The most common animals used were dogs (n=5). Other animals 
included cats (n=1), horses (n=1), farm animals (n=1), and hamsters (n=1). One study 
used both dogs and cats, and another study used both dogs and horses.  Of those that 
reported treatment lengths, treatments ranged from 10 weeks to 12 months. Sessions lasted 
between 40 minutes and 10 hours, with session frequency ranging from one session per 
week to seven sessions per week. Apart from the pet therapy study, sessions lasted up to 4 
hours with a frequency of either one session per week (n=3) or two sessions per week 
(n=3). The pet therapy study was less structured with treatment being the presence of a 
hamster in the participant’s room for 10 hours each day. One study included a follow-up 
assessment after the end of the treatment period, which was at 6 months. None of the 
studies were reviewed by an Institutional Animal Care and Use Committee (IACUC). 
 
 [TABLE 2] 
  
 For the primary outcomes, one study found a significant improvement in negative 
symptoms in the treatment group, as measured using the Scale for the Assessment of 
Negative Symptoms (SANS). Another study reported a significant improvement in positive 
and emotional symptoms in the treatment group, but no significant difference for negative 
symptoms. Two studies reported a significant improvement in negative symptoms within the 
treatment group but no significant differences in Positive and Negative Symptom Scale 
(PANSS) scores were found between the treatment and control group. One study found no 
significant differences in Brief Psychiatric Rating Scale (BPRS) scores. There were no 
significant differences between treatment and control groups for quality of life, as measured 
using the QOLS-N, EQ-5D, and the Brief World Health Organization Quality of Life 
Assessment (WHOQOL-BREF). One study reported a significantly lower score on the general 
health item of the EQ-5D within the treatment group at the end of the intervention. 
 For the secondary outcomes, two studies reported no significant differences in social 
functioning between treatment and control groups as measured using the LSP. One of these 
studies reported a significant improvement in social contact within the treatment group, 
which was not found within the control group. However, they also found a significant 
worsening of non-personal social behaviour. One study reported significant improvements in 
total Social Adaptive Functioning Evaluation (SAFE) scores and in scores on the social 
functioning subscale in the treatment group compared to control. Adverse effects were not 
reported in four of the included studies, and two studies reported no adverse effects.  
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Significant improvements were reported in treatment groups for self-esteem, self-
determination, self-efficacy (GSE), and anxiety. A significant reduction in violent incident 
reports was found in an equine-assisted psychotherapy (EAP) treatment group. One study 
also reported a significant reduction in salivary cortisol following AAT sessions. No significant 
differences were found between treatment and control groups for social support, salivary 
alpha-amylase as a measure of stress-relief, coping strategies, depression, intrusiveness, or 
other aggression measures. 
 Other outcomes of interest included adherence, animal recruitment (where animals 
were sourced from, e.g. from a charity such as Pets as Therapy, and degree of training that 
the animal had received), matching (between patients and animals), attrition, cost, dosage 
(number, duration, and frequency of sessions), and any barriers to providing AAT for 
schizophrenia (such as ethical barriers, health and hygiene, or patient and professional 
attitudes towards AAT). No information was provided regarding matching, cost, and barriers 
by any of the studies. Information regarding dosage are described elsewhere and presented 
in Table 2. One study reported significantly higher adherence to AAT (92.2%) than control 
(61.2%). High dropout rates were reported in one of the studies, in which 68% of 
participants from the treatment group completed the study and 93% from the control group 
completed the study. Dropout rates in other studies were as follows: 14.3%, 12.4%, 10%, 
and 8.3%. The majority of dropouts were reported as participants withdrawing from the 
study prior to the end of sessions (61.9%), with the remaining dropouts being those who 
did not attend any sessions (38.1%). Of those that reported sufficient information, the 
majority of dropouts across studies were from the treatment groups (86.2%). Animals were 
recruited from trainers, farmers, counsellors from a Pet Enrichment Therapy (PET) program, 
and an animal welfare centre. Animals were specially certified in two studies. In one study, 
although there was no official certification for therapy dogs in the country of study, physical 
and behavioural examinations were carried out by certified specialists.  
    





Risk of bias was assessed using the Cochrane risk of bias tool (Higgins et al., 2011), 
the results of which are presented in Figure 2. Risk of bias across studies is presented in 
Figure 3. 
Six studies were judged to be of unclear risk of bias for random sequence generation 
due to insufficient information regarding method of randomization. The remaining study 
reported that participants were allocated using computer randomization and so was judged 
as low risk of bias. 
There were no statements regarding allocation concealment in any of the included 
studies and so were all judged as unclear risk of bias.  
Most studies were judged to be of high risk of bias for blinding of participants and 
personnel due to the inability to blind individuals to the presence of an animal. While this 
was the case for all studies, two studies included active control groups, which may reduce 
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the risk of bias, and so were judged to be of unclear risk of bias. One study was judged to 
be of unclear risk of bias due to insufficient information regarding the control condition. 
Four studies used blind raters and so were judged as low risk of bias for blinding of 
outcome assessment. However, one of these studies was judged as high risk of bias for a 
separate outcome as staff were not blind at post-test. One study was judged as high risk of 
bias as only one neuropsychologist participated in the study and so could not be blinded. A 
low risk of bias judgement was made for a separate outcome as saliva samples were 
analysed by laboratory technicians who were blind to treatment. The remaining two studies 
were judged as unclear risk of bias due to insufficient information. 
  One study was judged as low risk of bias for incomplete outcome data as all 
participants completed the study. Four studies were judged as high risk of bias due to 
withdrawals and exclusions that may have imbalanced groups, and lack of intention-to-treat 
analysis and/or use of a per protocol analysis. The remaining two studies were judged as 
unclear risk of bias due to insufficient information. 
Two studies were judged to be of high risk of bias for selective outcome reporting. 
One study stated that they would investigate physiological and psychological aspects of 
schizophrenia in their aims, but no physiological results were reported, nor was there any 
mention of physiological measures in the methods. The second study did not fully report the 
results for one measure, instead reporting two out of three items. The remaining studies 
were judged to be of unclear risk of bias as study protocols were not available to be able to 
make a clear judgement.  
Other sources of bias included baseline imbalances, and funding from the Affinity 
Foundation, which promotes the benefits of pets for humans. Two studies were judged to 
be of unclear risk of bias for other sources due to insufficient information. Other sources of 
bias were not identified in the remaining three studies. 
Overall, there were few low risk of bias judgements made across the studies (10 out 
of 51), with a larger number of high risk (15 out of 51) and unclear risk of bias judgements 
(26 out of 51). Nurenberg et al. (2014) and Calvo et al. (2016) had the most ‘high risk’ 
judgements (5 out of 8) while Barak et al. (2001) had the most ‘low risk’ judgements (3 out 





The primary aim of the current review was to synthesise the published research to 
determine whether animal-assisted therapy is an effective treatment for schizophrenia based 
on results from randomised controlled trials. Meta-analysis was not possible in the review 
due to heterogeneity, particularly marked differences in outcome measures and 
interventions. Evidence for the effectiveness of animal-assisted therapy for the treatment of 
schizophrenia remains inconclusive and not sufficiently robust. This review identified mixed 
findings for the effectiveness of animal-assisted therapy for schizophrenia. Improvements 
were found for negative symptoms, positive and emotional symptoms, and SAFE scores, 
particularly the social functioning subscale, and on a number of measures of positive self-
view (self-esteem, self-efficacy, and self-determination). Some within-treatment group 
effects were found for improvements in negative symptoms, and social contact. There was 
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no evidence for any benefits to quality of life and some studies failed to find any 
improvements for symptoms from measurement using the PANSS or BPRS. There were also 
no improvements found on the Living Skills Profile (LSP), Coping Strategies Scale, or for 
social support. It is important to note that because of serious flaws in the included studies 
and the high risk of bias and unclear bias across the studies, makes the interpretation of 
results impossible. This review cannot make any conclusions based on the included studies. 
The potential benefit of AAT for negative symptoms, social difficulties, and negative 
self-view evident in this review are also noted in a number of observational studies. These 
include reports of significant reductions in symptoms, particularly negative symptoms 
following therapeutic riding (Cerino et al., 2011), as well as significant improvements in 
hedonic tone following AAT with a dog (Nathans-Barel et al., 2004). Significantly increased 
use of leisure time following AAT (Nathans-Barel et al., 2004), increased nonverbal 
communication (Kovács et al., 2006), increased prosocial behaviours (Marr et al., 2000), and 
increased scores on the Independent Living Skills Survey (ILSS), particularly for domestic 
activities and health subscale scores (Kovács  et al., 2004) have also been observed. 
Increases in measures of positive self-view have been found following therapeutic horseback 
riding, including increases in self-esteem (Bizub et al., 2003; Corring et al., 2013), sense of 
agency (Bizub et al., 2003), self-confidence, and self-efficacy (Corring et al., 2013). 
Lack of apparent evidence for benefits to quality of life in the current review may be 
due to the nature of the interventions used. Longer, and more frequent, interventions may 
be required to have a measurable impact on quality of life but it may be that AAT is not an 
effective treatment for targeting quality of life in schizophrenia patients. Results from a 
recent systematic review of dog-assisted interventions in health care identified 
improvements in quality of life in two out of three studies that included this measure 
(Lundqvist et al., 2017). However, the two studies that identified improvements looked at 
dementia patients, and the study included in the current review (Calvo et al., 2016) that did 
not show improvements, looked at schizophrenia. The worsening of non-personal social 
behaviour found in one study was concerning (Villalta-Gil et al., 2009). The authors noted 
that they did not focus on non-personal social behaviours in their intervention program (e.g. 
disruptive behaviours towards public objects). It is important that future studies take this 
into account to minimise any potential adverse effects.  
Another factor that may influence results is the types of treatment/s patients are 
receiving prior to enrolling in AAT. However, only one study (Calvo et al., 2016) provided 
detailed information regarding the medications that patients were taking prior to AAT and 
that all individuals were enrolled in a psychosocial rehabilitation programme. Berget et al. 
(2008, 2011) provided general information regarding medication (Table 2) but no 
information regarding other treatment/s. Due to the lack of information, it is not possible to 
determine whether current treatments had any effect on outcomes. Severity and duration of 
illness may also be an important factor in outcomes. However, there was heterogeneity in 
the reporting on duration and severity. Some studies reported years spent in long term care 
(Barak et al., 2001; Berget et al., 2008, 2011; Nurenberg et al., 2015; Villalta-Gil et al., 
2009), while other reported years since onset of illness (Calvo et al., 2016; Chu et al., 
2009). The remaining study only stated that cases of illness were chronic (Kung et al., 
2005). Again, it is difficult to determine the impact of duration and severity of illness on 
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outcomes. Future studies should provide complete reporting so that conclusions can be 
reached.  
The secondary aim of this review was to assess feasibility and potential barriers of 
providing AAT for schizophrenia patients, but little information was available in the included 
studies. No information was provided regarding costs of AAT, barriers faced by therapists or 
researchers, or matching of participants to animals. Without this information, it is not 
possible to adequately assess feasibility and future research should address these outcomes 
to improve replicability and expansion of the use of AAT. Adherence was reported by one 
study, which showed significantly higher adherence to AAT compared to control. The review 
highlights some concerns regarding dropout rates from interventions. Of the studies that 
reported dropout rates, the majority noted higher dropout rates for intervention groups 
compared to control groups. Reasons given for dropouts included fear of dogs, discharge 
from hospital, risk of harm to animals involved, and little interest in included species and 
work involved. Future research should address these issues and develop strategies to 
improve adherence, attrition, patients’ experiences of AAT, and take steps to ensure animal 
welfare. It is concerning that only one study made any mention of animal welfare (Calvo et 
al, 2016) and none of the studies were reviewed by an Institutional Animal Care and Use 
Committee (IACUC). Calvo et al. taught participants the concepts of animal welfare, 
assessed the welfare of the dogs before, during, and after the program, and excluded 
participants that exhibited behaviours that may have compromised the welfare of the dogs. 
It is vital that more studies address animal welfare sufficiently. Compromised animal welfare 
not only risks the health and wellbeing of the animal involved, but could also lead to less 
effective treatment if the animal is unable to perform well as a therapy animal. Dogs that 
are rated as more stressed by their owners and veterinarians are less likely to participate in 
social contact with an unfamiliar person (Lind et al., 2017). Risks to animals taking part in 
animal-assisted interventions have been noted in some studies, including the potential for 
mistreatment (Hatch, 2007), deliberate attempts to injure the animal, lethargy, and 
symptoms of depression (Heimlich, 2001). Future studies and animal-assisted intervention 
programmes should place a greater emphasis on animal welfare, as well as human 
wellbeing, taking a ‘One Welfare’ approach to recognise the interconnectedness of animal 
welfare, human wellbeing, and the environment (Pinillos et al., 2016). There are several 
guidelines available that provide information on animal welfare during animal-assisted 
interventions. The International Association of Human-Animal Interaction Organisations 
(IAHAIO) published the White Paper: Definitions for Animal Assisted Intervention and 
Guidelines for Wellness of Animals Involved in 2014 (Jegatheesan et al., 2014).  
 Due to limitations in the included studies, there is still a lack of evidence for the 
effectiveness of AAT for schizophrenia and results should be treated with caution. The 
limitations of the included studies are common across much of the literature and have been 
discussed at length in previous reviews (May et al., 2016; Crossman, 2017; Kazdin, 2017). 
Limitations identified in this review are presented and discussed in Table 3 with 
recommendations for future research. The number of high risk and unclear risk of bias 
decisions are of particular concern. The study that identified improvements in negative 
symptoms had unclear risk of bias for 7 out of 7 decisions (Kung et al., 2005). The study 
that identified improvements in social functioning had unclear risk of bias for 4 out of 7 
decisions (Barak et al., 2001). The study that identified improvements in self-efficacy had 
12 
 
unclear risk of bias for 3 out of 7 decisions and high risk of bias for 2 out of 7 decisions 
(Berget et al., 2008, 2011). The study that identified improvements in self-esteem and self-
efficacy had unclear risk of bias for 2 out of 7 decisions and high risk of bias for 3 out of 7 
decisions (Chu et al., 2009). Methodological issues (Table 3) combined with high and 
unclear risk of bias make the findings from the majority of studies included in this review 
uninterpretable. It is vital that future studies address these issues and follow the CONSORT 
guidelines to ensure accurate reporting of randomised controlled trials (Schulz et al., 2010). 
The poor state of the research field was first highlighted in a review in 1984 (Beck & 
Katcher, 1984). Thirty-four years later and some of the same common limitations are still 
being found across studies. Whilst some aspects of the research have improved over time 
(May et al., 2016), future research must address limitations to allow firm conclusions 
regarding the efficacy of AAT as a treatment for schizophrenia and to allow for changes to 
be made to current policy and practice. Rigorous, large-scale randomised controlled trials 
with long-term follow-up are needed to determine the true impacts of AAT for 
schizophrenia.  
     [Table 3] 
 
This review had a number of limitations: 1) we included studies of lower quality in 
order to be inclusive, 2) studies were limited to those reported in the English language due 
to a lack of resources, 3) we were unable to conduct a meta-analysis due to heterogeneity 
of studies. Strengths of this review include: 1) restriction to randomised controlled trials to 
assess the best available evidence, 2) inclusion criteria were not restricted to published 
articles from peer-reviewed journals, 3) inclusive and comprehensive search strategy 4) use 
of the Cochrane Tool for Assessing Risk of Bias. We used the Cochrane tool as it has been 
argued to be more reliable than subjective quality assessments (Higgins et al., 2011). As far 
as we are aware, this tool has not been used in other systematic reviews of animal-assisted 
interventions, although one study did use the Cochrane’s criteria list (Kamioka et al., 2014). 
Prior to this review, we identified only one other systematic review on AAT that included 
unpublished studies (Germain et al., 2018). Only one systematic review was identified that 
examined animal-assisted interventions and schizophrenia (Jormfeldt & Carlsson, 2018). 
However, this review was limited to equine-assisted interventions, peer-reviewed papers, 
papers published between 2000 and 2016, and studies that included participants aged 18-65 
years. 
In conclusion, based on the results from this review, it would be premature at this 
point to make any changes to patient care and policy to incorporate animals into therapy. 
Rigorous, large-scale randomised-controlled trials with long-term follow-up are first needed 
to determine the true impacts of AAT for schizophrenia. There is some promise for the 
treatment of negative symptoms and negative self-view but results remain inconclusive. It is 
important to highlight the methodological flaws and predominantly high and unclear risk of 
bias of the included studies. Because of this, it is not possible to confirm whether AAT is or 
is not effective in treating schizophrenia based on the included studies. Given this, the need 
for the further development of negative symptom interventions (Elis et al., 2013), and the 
substantial burden of disease (Charlson et al., 2018), further research is required to 
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Figure 1: PRISMA flow diagram of the selection of studies for inclusion in the systematic 
review to assess the effectiveness of AAT for schizophrenia. 
 
 
Figure 2: 'Risk of bias' summary: review authors' judgements about each risk of bias item 
for each included study. The risk of bias assessment was conducted by two independent 
reviews with agreements made through further discussion. 
+ represents low risk of bias 
- represents high risk of bias 
? represents unclear risk of bias 
 
Figure 3: Risk of bias graph: review authors' judgements about each risk of bias item 
presented as percentages across all included studies. 
 
 
 
